George Millen: Unscripted

With a new $195M credit facility led by JPMorgan Chase, DailyPay strengthens its position in the evolving world of employee financial wellness.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

Acorn Energy partners with AIO Systems to bring AI-driven monitoring to cell towers and data centers, targeting a market projected to exceed $13 billion.

With its founder stepping down, Acrelec gets new leadership from Glory Global Solutions, poised to drive aggressive growth in the competitive QSR tech market.

Smart scooter giant Niu Technologies posted record annual sales driven by China, but a sharp Q4 drop, especially abroad, clouds its global outlook.

Following a stellar Black Friday, Energizer is expanding its retail footprint and unveiling next-gen chargers at CES, challenging tech accessory giants.

Ironwood Pharma forecasts a massive profit jump by lowering its top drug's price, a bold move as it advances its rare disease pipeline for future growth.

The junior explorer has raised crucial capital to advance its drilling programs in Quebec's prolific gold belt, signaling strong investor confidence.

A new partnership aims to create a one-stop shop for crypto firms, combining regulatory licensing with institutional-grade digital asset custody.

Facing stock pressure, Dot Ai bets on seasoned sales leader Delores Rochester to scale its enterprise business in the booming Asset Intelligence market.

With recent FDA approval, Belgian MedTech firm Nyxoah prepares for a pivotal presentation of its unique, battery-free sleep apnea implant at JPM.

CES 2026 will see the debut of the xLean TR1, a robot vacuum that transforms into a handheld and claims to learn like a human. Is this the future?

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

The newly public logistics firm reports soaring H1 2025 profits and revenue, yet its stock price tells a different, more cautious story.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

The Canadian retailer's Q3 results show strong sales growth, but a sharp drop in net earnings reveals the high price of its ambitious turnaround plan.

Titan Mining's new funding aims to end a 70-year U.S. graphite production gap, a critical move for the nation's EV and energy independence goals.

Industrial giant Fastenal partners with the Belfast Giants, a strategic move blending global business ambition with deep-rooted community engagement in NI.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.